ES2029830T3 - Un procedimiento para preparar un derivado de 6-cetoprostaglandina e1. - Google Patents
Un procedimiento para preparar un derivado de 6-cetoprostaglandina e1.Info
- Publication number
- ES2029830T3 ES2029830T3 ES198787300755T ES87300755T ES2029830T3 ES 2029830 T3 ES2029830 T3 ES 2029830T3 ES 198787300755 T ES198787300755 T ES 198787300755T ES 87300755 T ES87300755 T ES 87300755T ES 2029830 T3 ES2029830 T3 ES 2029830T3
- Authority
- ES
- Spain
- Prior art keywords
- carbon atoms
- derivative
- group
- unsubstituted
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000004432 carbon atom Chemical group C* 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- ROUDCKODIMKLNO-CTBSXBMHSA-N 6-oxoprostaglandin E1 Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CC(=O)CCCCC(O)=O ROUDCKODIMKLNO-CTBSXBMHSA-N 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001414 amino alcohols Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000001120 cytoprotective effect Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
UN DERIVADO DE 6-CETO-PROSTAGLANDINA E1 DE LA FORMULA (I) (DONDE R1 REPRESENTA UN RESIDUO AMINOACIDO O AMINOALCOHOL, R2 REPRESENTA UN ENLACE SENCILLO O UN GRUPO ALQUILENO CON 1 A 4 ATOMOS DE CARBONO, R3 REPRESENTA (I) UN GRUPO ALQUILO CON 1 A 8 ATOMOS DE CARBONO, (II) UN GRUPO CICLOALQUILO CON 4 A 7 ATOMOS DE CARBONO, QUE PUEDE SER NO SUSTITUIDO O SUSTITUIDO POR AL MENOS UN GRUPO ALQUILO CON 1 A 8 ATOMOS DE CARBONO, (III) UN GRUPO FENILO O FENOXI, QUE PUEDE SER NO SUSTITUIDO O SUSTITUIDO POR CLORO, TRIFLUOROMETILO O ALQUILO DE 1 A 3 ATOMOS DE CARBONO, SI R2 REPRESENTA UN ENLACE SENCILLO R3 NO REPRESENTA FENOXI). SUS CLORATOS DE CICLODEXTRINA Y SUS SALES NO TOXICAS POSEEN ACTIVIDAD SELECTIVA CITOPROTECTORA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1672286 | 1986-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2029830T3 true ES2029830T3 (es) | 1992-10-01 |
Family
ID=11924155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES198787300755T Expired - Lifetime ES2029830T3 (es) | 1986-01-30 | 1987-01-28 | Un procedimiento para preparar un derivado de 6-cetoprostaglandina e1. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4783480A (es) |
| EP (1) | EP0232126B1 (es) |
| JP (1) | JPS62277352A (es) |
| AT (1) | ATE55598T1 (es) |
| DE (1) | DE3764277D1 (es) |
| ES (1) | ES2029830T3 (es) |
| GR (1) | GR3001054T3 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3708537A1 (de) * | 1987-03-13 | 1988-09-22 | Schering Ag | 6-oxoprostaglandin-e-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
| EP0386901A1 (en) * | 1989-02-20 | 1990-09-12 | Ono Pharmaceutical Co., Ltd. | Novel 5-hetero-6-oxo-PGE derivatives |
| CA2027814C (en) * | 1989-10-20 | 1996-07-30 | Ryuji Ueno | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds |
| US5288754A (en) * | 1992-02-04 | 1994-02-22 | Allergan, Inc. | Polar C-1 esters of prostaglandins |
| GB0119370D0 (en) * | 2001-08-08 | 2001-10-03 | Univ London | Therapeutic agent |
| DK1418905T3 (da) * | 2001-08-08 | 2007-09-10 | Pentraxin Therapeutics Ltd | Terapeutisk middel til depletering af en uönsket proteinpopulation fra plasma |
| GB0313386D0 (en) * | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU511711B2 (en) * | 1976-12-30 | 1980-09-04 | Upjohn Company, The | 6-Oxo and 5, 6-Dihalo prostaglandin analogues |
-
1987
- 1987-01-12 JP JP62003315A patent/JPS62277352A/ja active Pending
- 1987-01-28 DE DE8787300755T patent/DE3764277D1/de not_active Expired - Lifetime
- 1987-01-28 ES ES198787300755T patent/ES2029830T3/es not_active Expired - Lifetime
- 1987-01-28 US US07/007,657 patent/US4783480A/en not_active Expired - Fee Related
- 1987-01-28 AT AT87300755T patent/ATE55598T1/de active
- 1987-01-28 EP EP87300755A patent/EP0232126B1/en not_active Expired - Lifetime
-
1990
- 1990-11-06 GR GR90400873T patent/GR3001054T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0232126A3 (en) | 1987-11-25 |
| GR3001054T3 (en) | 1992-03-20 |
| ATE55598T1 (de) | 1990-09-15 |
| US4783480A (en) | 1988-11-08 |
| EP0232126B1 (en) | 1990-08-16 |
| DE3764277D1 (de) | 1990-09-20 |
| JPS62277352A (ja) | 1987-12-02 |
| EP0232126A2 (en) | 1987-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE55393T1 (de) | Wachstumsfoerderungsmittel fuer tiere. | |
| EP0092158A3 (en) | Thiazolidine compound and fungicidal composition containing it | |
| CA2011087A1 (en) | Use of trifluoromethylphenylazolylmethyloxiranes as crop protection agents | |
| PT83104B (en) | Novel guanidinomethylbenzoic acid derivatives | |
| DE3362894D1 (en) | 1-3-dihydro 4-(1-hydroxy-2-amino-ethyl)-2h-indol-2-one derivatives, their salts, process for their preparation, their use as medicines and compositions containing them | |
| ES2029830T3 (es) | Un procedimiento para preparar un derivado de 6-cetoprostaglandina e1. | |
| EP0357089A3 (en) | Novel cephem compound as an antimicrobial agent and its preparation | |
| ES8402581A1 (es) | Un procedimiento para preparar derivados de imidazol y triazol. | |
| JPS56103168A (en) | Thiazole derivative, its preparation, and antihistaminic agent containing the same | |
| EP0097023A3 (en) | Prostaglandin d derivatives, process for their preparation and compositions containing them | |
| EP0319993A3 (en) | Maltooligosaccharide derivatives and reagents for determination of amylase activity | |
| EP0099672A3 (en) | Trans-delta 2-prostaglandin d derivatives, process for their preparation and compositions containing them | |
| DE3563050D1 (en) | Intermediates for the preparation of prostaglandin analogues | |
| GB1455766A (en) | Pheno aldehydes | |
| ES8407322A1 (es) | Procedimiento para la preparacion de 7 -aciltio-15,16-metilen-3-oxo-17 -pregna-1,4-dien-21,17-carbolactonas | |
| ES2075365T3 (es) | Procedimiento para la preparacion de derivados de 3-alcoximetil cefalosporina. | |
| DE3788149D1 (de) | Prostazyklin-(PGI2)-Analoge. | |
| FI914525A0 (fi) | Foerening, anvaendning och framstaellning. | |
| KR850007588A (ko) | β-나프틸알킬아민의 제조방법 | |
| ES8304920A1 (es) | Un procedimiento para preparar derivados de n-acil-n-hidroxi-a minoacidos. | |
| BR8603787A (pt) | Compostos heterociclicos,e,processo de sua preparacao e aplicacao | |
| EP0285142A3 (en) | 3-acylamino-3-deoxyallose derivatives | |
| EP0308943A3 (en) | Agent for regulating the motional function of gastrointestinal tract | |
| KR860004844A (ko) | 아미노벤즈아미드 유도체의 제조방법 | |
| FI844184A0 (fi) | Isokinolinderivat och foerfarande foer framstaellning daerav. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 232126 Country of ref document: ES |